Resource Details


Interim guidance on diagnosis and management of PVL-associated Staphylococcal infections in the UK

Author(s)Health Protection Agency PVL Working Group: Dr Christine McCartney; Prof. Barry Cookson; Dr David Dance; Dr Chris Day; Prof. Brian Duerden; Dr Tony Elston; Dr Angela Kearns & Dr Marina Morgan.
AbstractThis interim guidance was prepared by a Health Protection Agency (HPA) Working Group and is based on a review of the literature and experiences of colleagues in the UK, Europe and the USA. This guidance will be revisited following review of a number of recent cases in the UK.
A new pattern of disease due to Panton - Valentine Leukocidin (PVL) - positive strains of Staphylococcus aureus is emerging in the UK and world-wide. PVL is a toxin, which destroys white blood cells and is carried by <2% of clinical isolates of S. aureus [1]. PVL can be detected in both meticillin sensitive S. aureus (MSSA) and meticillin resistant S. aureus (MRSA) . To date the majority of isolates causing infection in the UK have been MSSA. Community-associated MRSA (CA-MRSA) are more likely to produce PVL than hospital-associated MRSA. PVL-positive S. aureus are normally associated with necrotising pyogenic cutaneous infections and occasionally with cellulitis or tissue necrosis However, they can cause other severe invasive infections such as septic arthritis, bacteraemia, purpura fulminans or community-acquired necrotising pneumonia

Skin infections and Clinical Management to include antibiotic therapy and infection control
Necrotising pneumonia and Clinical Management (mainly supportive) to include antibiotic therapy, infection control and adjunctive treatment - Intravenous Immunoglobulin (IVIG)
Confirmation of clinical diagnosis
Date of publishing04/12/2006
Date of last revision by publisher03/13/2007
Date of last review by us06/14/2010
Bookmark this page Email this page to a friend Print this page



Twitter FeedTwitter Feed